A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant

Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte infusions (DLIs) have been reported to control disease, but the...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Richard LeBlanc, Stéphanie Thiant, Rafik Terra, Imran Ahmad, Jean-Sébastien Claveau, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Silvy Lachance, Thomas Kiss, Denis-Claude Roy, Guy Sauvageau, Jean Roy
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2024-11-01
Serie:	Current Oncology
Soggetti:	allogeneic hematopoietic cell transplant donor lymphocyte infusion minimal measurable disease multiple myeloma
Accesso online:	https://www.mdpi.com/1718-7729/31/11/535
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!